Get the Stockscreener App
8.74
0.34%
-0.03
Kura Oncology Inc stock is traded at $8.74, with a volume of 3.23M.
It is down -0.34% in the last 24 hours and down -5.92% over the past month.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
See More
Previous Close:
$8.77
Open:
$8.76
24h Volume:
3.23M
Relative Volume:
1.93
Market Cap:
$775.89M
Revenue:
$67.48M
Net Income/Loss:
$-278.67M
P/E Ratio:
-2.7507
EPS:
-3.1774
Net Cash Flow:
$-70.70M
1W Performance:
-14.31%
1M Performance:
-5.92%
6M Performance:
-26.86%
1Y Performance:
+33.03%
1-Day Range:
$8.555
$9.21
1-Week Range:
$8.555
$10.17
52-Week Range:
$5.45
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
8.74 | 778.55M | 67.48M | -278.67M | -70.70M | -3.1774 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40 - Moomoo
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), Align Tech (ALGN) - The Globe and Mail
UBS Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Director at Kura Oncology (NASDAQ: KURA) receives 35,000-share option grant - Stock Titan
Kura Oncology (KURA) director receives grant of 35,000 stock options at $8.77 - Stock Titan
Kura Oncology (KURA) awards director stock options at $8.77 strike - Stock Titan
Kura Oncology (KURA) director receives 35,000 options at $8.77 strike price - Stock Titan
Kura Oncology (KURA) director Carol Schafer granted 35,000 stock options - Stock Titan
Director Mary Szela awarded 35,000 Kura Oncology (KURA) options - Stock Titan
Kura Oncology (KURA) director receives option grant for 35,000 shares at $8.77 - Stock Titan
[8-K] Kura Oncology, Inc. Reports Material Event - Stock Titan
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 - Moomoo
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating - Investing.com
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Citizens reiterates Kura Oncology stock rating on FIT-001 data - Investing.com
Kura Oncology Inc ASCO Investor Event Transcript - GuruFocus
KURA Highlights Promising Data for Darlifarnib in KRAS-Mutant Ca - GuruFocus
Kura Oncology reports phase 1a data for cancer drug combination - Investing.com UK
Kura Oncology reports phase 1a data for cancer drug combination By Investing.com - Investing.com Canada
Kura Oncology Reports Promising Phase 1a Results for Darlifarnib in Multiple KRAS-Mutant Cancers and Announces New Platform Study - Quiver Quantitative
Kura Oncology Highlights Darlifarnib’s Potential as a - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Kura Oncology Stock Hits Day Low of $9.03 Amid Price Pressure - Markets Mojo
Kura Oncology, Kyowa Kirin report trial results for AML drug By Investing.com - Investing.com South Africa
Kura Oncology, Kyowa Kirin report trial results for AML drug - Investing.com
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML - The Manila Times
Blood journal reports 87% response with Kura AML drug combo - Stock Titan
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology Stock Hits Day Low of $10.39 Amid Price Pressure - Markets Mojo
Citizens reiterates Kura Oncology stock rating on FTI platform progress By Investing.com - Investing.com Australia
Citizens reiterates Kura Oncology stock rating on FTI platform progress - Investing.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacific Edge Limited (OtherPFGTF), Kura Oncology (KURA) and Eli Lilly & Co (LLY) - The Globe and Mail
Precision Trading with Kura Oncology Inc. (KURA) Risk Zones - Stock Traders Daily
KURA Stock Price, Quote & Chart | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
KURA: Strong launch and clinical data drive optimism for growth in AML and solid tumor markets - TradingView
KURA: Strong launch and robust clinical data position therapies for major growth in AML and solid tumors - TradingView
KURA: Promising Results from FIT-001 Trial of Darlifarnib - GuruFocus
Kura Oncology reports strong tumor shrinkage with darlifarnib + adagrasib in KRAS G12C-mutated cancers. - Pluang
Kura Oncology reports tumor shrinkage in cancer drug trial By Investing.com - Investing.com South Africa
Kura Oncology reports tumor shrinkage in cancer drug trial - Investing.com
Kura Oncology Reports Promising Phase 1 Results for Darlifarnib in Combination with Adagrasib in KRAS G12C-Mutated Tumors - Quiver Quantitative
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS ... - Eagle-Tribune
Kura Oncology Reports Strong Clinical Activity and Safety - GlobeNewswire
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors - Sahm
Kura Oncology’s SWOT analysis: biotech stock faces launch test By Investing.com - Investing.com India
Kura Oncology’s SWOT analysis: biotech stock faces launch test - Investing.com UK
Insider Sell Alert: Brian Powl Sells 10,000 Shares of Kura Oncol - GuruFocus
Kura Oncology (KURA) CCO sells 10,000 shares in planned trade - Stock Titan
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):